Core Insights - Baiyang Pharmaceutical has signed an investment agreement with ZAP Medical System, Ltd. to subscribe to its E-series preferred shares, aiming to deepen cooperation and resource integration [1] - The company plans to sign a commercialization agreement with ZAP Surgical Systems, Inc. for exclusive operational rights of the ZAP-X® radiosurgery robot and related accessories in mainland China and Hong Kong and Macau [1][2] - ZAP-X is a pioneering radiosurgery robot designed for treating intracranial and neck tumors, featuring a complete self-shielding function that enhances accessibility without the need for expensive traditional radiation shielding facilities [2] Company Developments - Baiyang Pharmaceutical is entering the precision radiotherapy sector, indicating a strategic move to enhance its international competitiveness [3] - The company is optimistic about ZAP's potential in the precision radiotherapy market and plans to support the ZAP-X's development through technology research, large-scale production, and market promotion [3] - Baiyang Pharmaceutical has established a diverse brand matrix in various medical fields, including OTC, prescription drugs, and oncology, and is making strides in high-end medical devices [2]
百洋医药投资全球放疗引领者ZAP，拟承接其首创自屏蔽放疗设备商业化权益